Table I.
Comparison of the ability of reducing-end-derivatized and underivatized oligogalacturonides to alter TCL explant morphogenesis
| Oligogalacturonide | Morphogenetic Switch Concentration | Derivatized Oligogalacturonide | Morphogenetic Switch Concentration |
|---|---|---|---|
| μm | μm | ||
| G16 | 0.26 | G16-B | 0.65 |
| G15 | 0.15 | G13-B | 0.21 |
| G12 | 0.058 | G13-T | 0.15 |
| G10 | 0.83 | G13-R | 0.37 |
| G9 | 2.6 | G10-B | 1.7 |
| G7 | >2.6 | G8-B | >2.6 |
The concentration of each oligogalacturonide that induces a distinct change in the overall TCL explant morphology is reported as the morphogenetic switch concentration (as defined in the text). The values given for each oligogalacturonide are the averages of two independent bioassays, with the exception of the value for G12, which is the average of 12 independent experiments (sd = 0.033 μm).